Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Efonidipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.96 |
| ▸ | CACNA1C | Q13936 | 9/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efonidipine SCHEMBL909287 | 0.99 | ABCB1 (0.95) | ABCB1CACNA1CLMNACYP1A2CYP3A4 | |
| Efonidipine SCHEMBL909286 | 0.99 | ABCB1 (0.95) | ABCB1CACNA1CLMNACYP1A2CYP3A4 | |
| Efonidipine SCHEMBL1649423 | 0.99 | ABCB1 (0.93) | ABCB1CACNA1CLMNACYP1A2CYP3A4 | |
| Efonidipine SCHEMBL49637 | 0.98 | ABCB1 (1.00) | ABCB1CACNA1CLMNACYP1A2CYP3A4 | |
| Efonidipine SCHEMBL49638 | 0.98 | ABCB1 (1.00) | ABCB1CACNA1CLMNACYP1A2CYP3A4 | |
| Efonidipine SCHEMBL29379054 | 0.98 | ABCB1 (1.00) | ABCB1CACNA1CLMNACYP1A2CYP3A4 | |
| Efonidipine SCHEMBL29410289 | 0.98 | ABCB1 (1.00) | ABCB1CACNA1CLMNACYP1A2CYP3A4 | |
| Efonidipine SCHEMBL349046 | 0.97 | ABCB1 (0.99) | ABCB1CACNA1CLMNACYP1A2CYP3A4 | |
| Efonidipine SCHEMBL332377 | 0.97 | ABCB1 (0.99) | ABCB1CACNA1CLMNACYP1A2CYP3A4 | |
| Efonidipine SCHEMBL28844127 | 0.97 | ABCB1 (0.97) | ABCB1CACNA1CLMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1780823-A | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC (JP) | 2006-05-31 | — | — | CN | claimed |
| CN-102573913-B | Biodegradable polyethylene glycol-based water-insoluble hydrogels | ASCENDIS PHARMA AS | 2014-06-18 | — | — | CN | disclosed |
| CN-1893946-A | Use of pyrazole derivatives for the preparation of medicaments for the prevention and treatment of dyslipidemias and diseases associated with dyslipidemias and/or obesity | SANOFI AVENTIS (FR) | 2007-01-10 | — | — | CN | disclosed |
| CN-1780823-A | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC (JP) | 2006-05-31 | — | — | CN | disclosed |